ES2192456A1 - Composicion farmaceutica de una vez al dia que contiene brivudina - Google Patents

Composicion farmaceutica de una vez al dia que contiene brivudina

Info

Publication number
ES2192456A1
ES2192456A1 ES200101566A ES200101566A ES2192456A1 ES 2192456 A1 ES2192456 A1 ES 2192456A1 ES 200101566 A ES200101566 A ES 200101566A ES 200101566 A ES200101566 A ES 200101566A ES 2192456 A1 ES2192456 A1 ES 2192456A1
Authority
ES
Spain
Prior art keywords
brivudine
once
pharmaceutical composition
day pharmaceutical
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200101566A
Other languages
English (en)
Other versions
ES2192456B1 (es
Inventor
Alessandro Casini
Bettina Stubinski
Attilio Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Menarini Ricerche SpA
Original Assignee
Berlin Chemie AG
Menarini Ricerche SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG, Menarini Ricerche SpA filed Critical Berlin Chemie AG
Publication of ES2192456A1 publication Critical patent/ES2192456A1/es
Application granted granted Critical
Publication of ES2192456B1 publication Critical patent/ES2192456B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composición farmacéutica de una vez al día que contiene brivudina. Se describe la actividad de brivudina administrado una vez al día en infecciones agudas producidas por herpes zoster y en la neuralgia post-herpética, y las composiciones del mismo. Las relaciones de riesgo calculadas a partir de la regresión de Cox con covariables aleatorias e intervalo de confianza unilateral inferior del 95%, comparación de 1 x 125 mg de brivudina frente a 5 x 800 mg de aciclovir (por población de protocolo).
ES200101566A 2001-01-03 2001-07-05 Composicion farmaceutica de una vez al dia que contiene brivudina. Expired - Fee Related ES2192456B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000009A ITMI20010009A1 (it) 2001-01-03 2001-01-03 Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
IT2001A000009 2001-01-03

Publications (2)

Publication Number Publication Date
ES2192456A1 true ES2192456A1 (es) 2003-10-01
ES2192456B1 ES2192456B1 (es) 2005-02-01

Family

ID=11446384

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200101566A Expired - Fee Related ES2192456B1 (es) 2001-01-03 2001-07-05 Composicion farmaceutica de una vez al dia que contiene brivudina.

Country Status (20)

Country Link
AT (1) AT6141U1 (es)
BE (1) BE1014522A5 (es)
CH (1) CH695662A5 (es)
CZ (1) CZ20012464A3 (es)
DK (1) DK177084B1 (es)
ES (1) ES2192456B1 (es)
FI (1) FI20011446A (es)
FR (1) FR2818907B1 (es)
GB (1) GB2370771A (es)
GR (1) GR1004012B (es)
HR (1) HRPK20010345B3 (es)
HU (1) HUP0102816A3 (es)
IE (1) IE20010413A1 (es)
IT (1) ITMI20010009A1 (es)
NL (1) NL1018431C2 (es)
PL (1) PL348480A1 (es)
PT (1) PT102642B (es)
SE (1) SE0102309L (es)
SK (1) SK287043B6 (es)
UA (1) UA76402C2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239527A1 (es) * 2004-03-01 2005-09-16 M. Cruz Fernandez Gonzalez Liquido que cura el herpes zoster.

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104857A1 (en) * 1982-09-28 1984-04-04 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0143987A1 (en) * 1983-10-31 1985-06-12 Anna Gioia Stendardi Therapeutic compositions endowed with antiviral activity
US5446031A (en) * 1991-04-24 1995-08-29 Yamasa Shuyu Kabushiki Kaisha 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104857A1 (en) * 1982-09-28 1984-04-04 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0143987A1 (en) * 1983-10-31 1985-06-12 Anna Gioia Stendardi Therapeutic compositions endowed with antiviral activity
US5446031A (en) * 1991-04-24 1995-08-29 Yamasa Shuyu Kabushiki Kaisha 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LGEMÍLLER J. y col. Determination of (E)-5-(2-bromovinyl)-2^- deoxyuridine in plasma and urine by capillary electrophoresis. Journal of Chromatography B, 1999, Vol. 726, Nö 1-2, páginas 261-268, ISSN 004165297. Página 261, columna derecha. *
Treatment with Brivudin: Once daily: That is enough for effective Zoster therapy, [en línea], 18 diciembre 2000, [recuperado el 20.05.2003]. Recuperado de Internet: <URL:http://www.arztonline.de/docs/2000/12/18/228a0403.asp#top>. Todo el documento. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239527A1 (es) * 2004-03-01 2005-09-16 M. Cruz Fernandez Gonzalez Liquido que cura el herpes zoster.

Also Published As

Publication number Publication date
CH695662A5 (de) 2006-07-31
FR2818907B1 (fr) 2006-05-26
GB0110682D0 (en) 2001-06-20
HUP0102816A2 (en) 2002-10-28
NL1018431C2 (nl) 2002-07-05
IE20010413A1 (en) 2003-04-16
GR1004012B (el) 2002-11-01
FI20011446A0 (fi) 2001-07-03
ITMI20010009A1 (it) 2002-07-03
ITMI20010009A0 (it) 2001-01-03
SE0102309D0 (sv) 2001-06-28
GR20010100322A (el) 2002-10-08
AT6141U1 (de) 2003-05-26
SE0102309L (sv) 2002-07-04
PT102642A (pt) 2002-07-31
GB2370771A (en) 2002-07-10
HRPK20010345B3 (en) 2005-02-28
UA76402C2 (en) 2006-08-15
DK200101019A (da) 2002-07-04
PT102642B (pt) 2003-06-30
PL348480A1 (en) 2002-07-15
CZ20012464A3 (cs) 2002-08-14
HRP20010345A2 (en) 2003-08-31
SK287043B6 (sk) 2009-10-07
HU0102816D0 (en) 2001-09-28
FR2818907A1 (fr) 2002-07-05
ES2192456B1 (es) 2005-02-01
DK177084B1 (da) 2011-07-11
BE1014522A5 (fr) 2003-12-02
SK9572001A3 (en) 2003-03-04
FI20011446A (fi) 2002-07-04
HUP0102816A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
AU7490700A (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
YU36700A (sh) Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
EE200000532A (et) Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ningkombineeritud preparaat kasutamiseks HIV nakkusera
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
PL363313A1 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
BG108516A (en) Pharmaceutical formulation
HRP20040584A2 (en) Dosage regimen and pharmaceutical composition for emergency contraception
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
WO2002024203A3 (en) Controlled release formulations for oral administration
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
DE60128263D1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
ES2192456A1 (es) Composicion farmaceutica de una vez al dia que contiene brivudina
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
GR3019776T3 (en) Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof
EP1161254A4 (en) TREATMENT OF AUTOIMMUNE DISEASES WITH AMERICAN GINSENG EXTRACT
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
James AZT twice-daily tablets approved: dosing concerns
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031001

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192456B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211026